ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1659

The Clinical Relevance of a Repeat Biopsy in Lupus Nephritis (LN) Flares

Milagros Ricse1, Javier Narváez2, Gloria Albert1, Paula Estrada1, Sergi Heredia1, Andrea Zacarias1, Helena Borrell1, Eulalia Armengol1, Xavier Fulladosa3, Joan Torras3, Olga Capdevila4, Francesca Mitjavila4 and Joan Miquel Nolla1, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 3Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: biopsies, Clinical practice, Nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Renal biopsy is the gold standard for assessing renal activity and hence guiding treatment. Whether a repeat renal biopsy is helpful during flares of LN remains unclear. In the present study, we retrospectively reviewed LN patients who had more than one renal biopsy, in the hope of finding the clinical advantage of repeat biopsy

Methods:  The sample comprised 243 patients with systemic lupus erythematosus (SLE) treated between 1980 and 2013 at a tertiary university hospital that does not treat pediatric populations. The patients were registered in a specific database. From a total of 126 patients with LN, we selected those who underwent 2 renal biopsies for analysis. Renal biopsies were evaluated according to the WHO classification  or the ISN/RPS classification (in use since 2004).

Results: We identified 28 SLE patients with LN for whom it was possible to compare reference and repeat biopsies. In total, 56 renal biopsies were considered. Overall, in 14 patients (50%), paired biopsies showed changes in the pathological pattern. Table 1 shows the pathological classification on repeat biopsy:

 

Reference biopsy

 

 

Repeat biopsy

 

Class II Mesangial LN  

 N=9

 

 

1 switched to Class I

2 no shift in pathological class

6 switched to higher grade nephritis (Class IV: 3 cases, Class V: 3 cases).

 

 

Class III Focal LN

N=4

 

 

2 no shift in pathological class

2 switched to higher grade nephritis (Class IV: 1 case, Class V: 1 case)

 

 

Class IV Diffuse LN

N= 13

 

 

1 switched to Class II and 3 to Class III

9 no shift in pathological class

 

 

Class V Membranous LN

N=2

 

 

1 switched to Class IV

1 no shift in pathological class

 

In the subgroup of patients with Class II mesangial LN, the repeat biopsy showed a transformation to a higher grade of nephritis (Class IV or V) in 67% of the cases.

In contrast, in most patients (65%) with proliferative classes (III and IV), there was no shift in histological class on repeat biopsy. Of the 2 patients with Class V membranous LN, only 1 changed to a proliferative class. Clinically significant class switches during LN flares were more frequent in patients with non-proliferative lesions (Classes II and V) than those with proliferative lesions (classes III and IV) in their reference biopsy (p<0.05).

The mean renal activity index on first biopsy was 8.85 (SD: 4.43) and on repeat biopsy it was 7.26 (SD: 3.84) (p = 0.315). The mean chronicity index for the first biopsy was 1.95 (SD: 2.53) and for the repeat biopsy it was 2.52 (SD: 2.39) (p<0.001).

The pathological transition could not be predicted by any clinical characteristics. After the repeat biopsy, 10 (36%) of patients had a change of treatment regimen: 8 received an increase in immunosuppression; while in 2 cases immunosuppressive therapy was decreased or stopped.

 Conclusion: Pathological conversion was highly prevalent (50%) in patients with LN. Overall, 66% of cases with class II mesangial LN in a reference biopsy showed transformation to a higher grade of nephritis (class IV or V) on repeat biopsy, so early repeat biopsy is advisable for this subgroup of patients. In contrast, in most patients (65%) with proliferative Classes (III and IV) in a reference biopsy, there was no shift in histological class on repeat biopsy.

Repeat biopsy might be helpful in guiding treatment, both to identify those patients for whom it is necessary to intensify immunosuppression therapy, and to avoid unnecessary increased immunosuppression therapy in others.


Disclosure:

M. Ricse,
None;

J. Narváez,
None;

G. Albert,
None;

P. Estrada,
None;

S. Heredia,
None;

A. Zacarias,
None;

H. Borrell,
None;

E. Armengol,
None;

X. Fulladosa,
None;

J. Torras,
None;

O. Capdevila,
None;

F. Mitjavila,
None;

J. M. Nolla,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-clinical-relevance-of-a-repeat-biopsy-in-lupus-nephritis-ln-flares/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology